Nichole Tucker

CLN-619 has emerged for the treatment of advanced solid tumors in the clinical trial setting. Early results are promising, says lead investigator Judy Wang, MD

Results from the phase 1 EQUILIBRIUM study signal better outcomes for patients with newly diagnosed, MGMT methylated glioblastoma.

In an interview with Targeted Oncology during the International Liver Cancer Association Annual Conference 2023, Tim F. Greten, MD, discussed the key highlights from his presentation on tissue biopsy, and his thoughts on the opposing argument in favor of liquid biopsy.

Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.

In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with patients with intrahepatic cholangiocarcinoma.

Activation of the JAK/STAT pathway with ruxolitinib may be a future option for patients with newly diagnosed, high-grade glioma.

In an interview with Targeted Oncology, Penn Medicine’s Qian Wang, MD, MPH, gives an in-depth overview of the molecular targets in the small cell lung cancer field.

In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.

In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.

MJH Life Sciences ™ - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.